Invented by Emrys Jones, Steven Derek Pringle, Keith Richardson, James Ian Langridge, Zoltan Takats, Imperial College of Science Technology and Medicine, Micromass UK Ltd

Cell population analysis is a rapidly growing field in the healthcare and life sciences industry. It involves the study and characterization of different types of cells within a population, providing valuable insights into various biological processes and disease states. The market for cell population analysis is expanding at a significant rate, driven by advancements in technology, increasing research activities, and the rising demand for personalized medicine. One of the key factors contributing to the growth of the cell population analysis market is the development of innovative and advanced techniques. Traditional methods of cell analysis, such as flow cytometry, have been widely used for several years. However, recent advancements in imaging technologies, such as high-content screening and single-cell analysis, have revolutionized the field. These techniques allow researchers to analyze individual cells within a population, providing more detailed and accurate information. The increasing focus on personalized medicine is also driving the demand for cell population analysis. With the growing understanding that each individual is unique, there is a need for tailored treatment strategies. Cell population analysis plays a crucial role in identifying specific cell types and their characteristics, enabling the development of targeted therapies. By analyzing the heterogeneity within a population, researchers can identify biomarkers and potential drug targets, leading to more effective treatments. Furthermore, the rising prevalence of chronic diseases, such as cancer and autoimmune disorders, is fueling the demand for cell population analysis. These diseases are often characterized by abnormal cell populations, which can be identified and studied through advanced analysis techniques. By understanding the composition and behavior of these cells, researchers can gain insights into disease progression, develop diagnostic tools, and design personalized treatment plans. The market for cell population analysis is also benefiting from the increasing investment in research and development activities. Governments, academic institutions, and pharmaceutical companies are allocating significant funds to advance our understanding of cellular biology and develop innovative therapies. This investment is driving the development of new technologies and tools for cell population analysis, further propelling market growth. Additionally, the growing adoption of cell population analysis in drug discovery and development is contributing to market expansion. Pharmaceutical companies are increasingly incorporating cell-based assays and screening techniques in their drug discovery pipelines. By analyzing the effects of potential drug candidates on specific cell populations, researchers can assess their efficacy and safety profiles, reducing the time and cost involved in the drug development process. Geographically, North America dominates the cell population analysis market, owing to the presence of a well-established healthcare infrastructure, significant research funding, and a large number of pharmaceutical companies. However, the market is witnessing substantial growth in Asia Pacific, primarily due to the increasing focus on healthcare infrastructure development and rising research activities in countries like China and India. In conclusion, the market for cell population analysis is experiencing significant growth, driven by technological advancements, increasing research activities, and the demand for personalized medicine. The development of innovative techniques, the focus on personalized therapies, the rising prevalence of chronic diseases, and the investment in research and development activities are key factors propelling market expansion. As the field continues to evolve, cell population analysis will play a crucial role in advancing our understanding of cellular biology and improving patient outcomes.

The Imperial College of Science Technology and Medicine, Micromass UK Ltd invention works as follows

The method involves: “(a) using a device to produce smoke, vapour or aerosol from a cell population in vitro or in vivo; (b), mass analysing or ion-mobility analysing the smoke, vapour or aerosol, or ions that are derived from it, to obtain spectrometric information; and (c), analysing these spectrometric results to identify or characterise the target cell populations or any cells or compounds within them.

Background for Cell Population Analysis

Ambient Ionisation Ion Sources

Rapid Ionisation and Evaporation Mass Spectrometry” (?REIMS?)

General Methods” of the Invention

Target cell populations

Melanoma?LOX IMVI; MALME-3M; SK-MEL-2; SK-MEL-5; SK-MEL-28; M19-MEL; UACC-62; USACC-257; M14;

Leukemia?CCRF-CEM; K-562; MOLT-4; HL-60; RPMI-8226; SR.

Analysis or Authenticity of Identity

Analysis Of Infection

Properties Cell Populations

Drug Discovery and Screening of Agents e.g. Cytotoxic Agents

Analysis Of A Change

Environmental Conditions

Analysis Lipid Requirements

Isotope Studies

Analysis Radio-Tracers

Isogenic cell populations


Culture Media

Oxidative Stress

Identification of Utilisation/Production Cell Populations

Substance Utilisation/Production and Quality Control

Click here to view the patent on Google Patents.